{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:40:19Z","timestamp":1791186019363,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD.<\/jats:p>\n               <jats:p>Introduction: Bazedoxifene is a novel selective estrogen receptor modulator that has increased BMD and bone strength in experimental models, without stimulating breast or uterus. This 24-mo, randomized, double-blind study assessed the efficacy and safety of three doses of bazedoxifene compared with placebo and raloxifene in the prevention of postmenopausal osteoporosis.<\/jats:p>\n               <jats:p>Materials and Methods: Healthy postmenopausal women with a BMD T-score at the lumbar spine or femoral neck between \u20131.0 and \u22122.5 or clinical risk factors for osteoporosis were randomly assigned to one of five groups: bazedoxifene 10, 20, or 40 mg\/d, placebo, or raloxifene 60 mg\/d. All women received elemental calcium. Efficacy outcomes included changes from baseline through 24 mo in BMD of the lumbar spine, hip, femoral neck, and femoral trochanter and biomarkers of bone metabolism.<\/jats:p>\n               <jats:p>Results: The intent-to-treat population included 1434 women (mean age, 58 yr; mean time from last menstrual period, 11 yr). All doses of bazedoxifene and raloxifene prevented bone loss, whereas in the placebo group, there was significant loss of BMD at all skeletal sites. Mean differences in percent change in lumbar spine BMD from baseline to 24 mo relative to placebo were 1.08 \u00b1 0.28%, 1.41 \u00b1 0.28%, 1.49 \u00b1 0.28%, and 1.49 \u00b1 0.28% for 10, 20, and 40 mg bazedoxifene and 60 mg raloxifene, respectively (p &amp;lt; 0.001 for all comparisons). Comparable BMD responses were observed at other body sites. Significant and comparable decreases in serum osteocalcin and C-telopeptide levels from baseline and relative to placebo with active treatment were observed as early as 3 mo and were sustained through study conclusion (p &amp;lt; 0.001). Overall incidences of adverse events, serious adverse events, and discontinuations caused by adverse events were similar between groups. The most common adverse events included headache, infection, arthralgia, pain, hot flush, and back pain.<\/jats:p>\n               <jats:p>Conclusions: Treatment with bazedoxifene prevented bone loss and reduced bone turnover equally as well as raloxifene and was generally well tolerated in postmenopausal women with normal\/low BMD.<\/jats:p>","DOI":"10.1359\/jbmr.071206","type":"journal-article","created":{"date-parts":[[2007,12,11]],"date-time":"2007-12-11T13:13:13Z","timestamp":1197378793000},"page":"525-535","source":"Crossref","is-referenced-by-count":194,"title":["Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled Study"],"prefix":"10.1093","volume":"23","author":[{"given":"Paul D","family":"Miller","sequence":"first","affiliation":[{"name":"Colorado Center for Bone Research, Lakewood, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadi A","family":"Chines","sequence":"additional","affiliation":[{"name":"Wyeth Research, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Center for Clinical and Basic Research, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C","family":"Hoeck","sequence":"additional","affiliation":[{"name":"Center for Clinical and Basic Research, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Kendler","sequence":"additional","affiliation":[{"name":"Osteoporosis Research Centre, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grattan","family":"Woodson","sequence":"additional","affiliation":[{"name":"Atlanta Research Center, Decatur, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B","family":"Levine","sequence":"additional","affiliation":[{"name":"Wyeth Research, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Constantine","sequence":"additional","affiliation":[{"name":"Wyeth Research, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre D","family":"Delmas","sequence":"additional","affiliation":[{"name":"University of Lyon and INSERM Research Unit 831, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319550103100_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","journal-title":"JAMA"},{"key":"2024020319550103100_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s001980050224","article-title":"Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis","volume":"10","author":"Genant","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024020319550103100_bib3","author":"National Osteoporosis Foundation","year":"2006"},{"key":"2024020319550103100_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"Perspective. How many women have osteoporosis?","volume":"7","author":"Melton","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020319550103100_bib5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1532-5415.1995.tb05557.x","article-title":"Late physical and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study","volume":"43","author":"Greendale","year":"1995","journal-title":"J Am Geriatr Soc"},{"key":"2024020319550103100_bib6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1996.00440130053006","article-title":"Mortality following fractures in older women. The study of osteoporotic fractures","volume":"156","author":"Browner","year":"1996","journal-title":"Arch Intern Med"},{"key":"2024020319550103100_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020319550103100_bib8","volume-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","author":"U.S. Department of Health and Human Services","year":"2004"},{"key":"2024020319550103100_bib9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1524-4733.2003.65261.x","article-title":"Methodology for estimating current and future burden of osteoporosis in state populations: Application to Florida in 2000 through 2025","volume":"6","author":"Burge","year":"2003","journal-title":"Value Health"},{"key":"2024020319550103100_bib10","first-page":"115","article-title":"Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"2024020319550103100_bib11","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1172\/JCI28550","article-title":"Estrogen deficiency and bone loss: An inflammatory tale","volume":"116","author":"Weitzmann","year":"2006","journal-title":"J Clin Invest"},{"key":"2024020319550103100_bib12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"key":"2024020319550103100_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00198-004-1674-6","article-title":"Prediction of incident osteoporotic fractures in elderly women using the free estradiol index","volume":"16","author":"Devine","year":"2005","journal-title":"Osteoporos Int"},{"key":"2024020319550103100_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.GME.0000086467.82759.DA","article-title":"Recency and duration of postmenopausal hormone therapy: Effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study","volume":"10","author":"Barrett-Connor","year":"2003","journal-title":"Menopause"},{"key":"2024020319550103100_bib15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003","volume":"9","author":"Hodgson","year":"2003","journal-title":"Endocr Pract"},{"key":"2024020319550103100_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-004-1813-0","article-title":"Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation","volume":"16","author":"Delmas","year":"2005","journal-title":"Osteoporos Int"},{"key":"2024020319550103100_bib17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.gme.0000222475.93345.b3","article-title":"Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society","volume":"13","author":"North American Menopause Society","year":"2006","journal-title":"Menopause"},{"key":"2024020319550103100_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","article-title":"Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation","volume":"949","author":"Komm","year":"2001","journal-title":"Ann NY Acad Sci"},{"key":"2024020319550103100_bib19","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1021\/jm010086m","article-title":"Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens","volume":"44","author":"Miller","year":"2001","journal-title":"J Med Chem"},{"key":"2024020319550103100_bib20","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"2024020319550103100_bib21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","article-title":"Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women","volume":"105","author":"Ronkin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"2024020319550103100_bib22","author":"Ronkin","year":"2001"},{"issue":"Suppl 7","key":"2024020319550103100_bib23","first-page":"S14","article-title":"Effects of bazedoxifene TSE-424, a novel tissue selective estrogen receptor modulator SERM, on the incidence of breast pain","volume":"14","author":"Boudes","year":"2003","journal-title":"Osteoporos Int"},{"key":"2024020319550103100_bib24","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"2024020319550103100_bib25","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","article-title":"Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials","volume":"160","author":"Johnston","year":"2000","journal-title":"Arch Intern Med"},{"key":"2024020319550103100_bib26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bone.2007.06.010","article-title":"Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?","volume":"41","author":"Seeman","year":"2007","journal-title":"Bone"},{"issue":"S1","key":"2024020319550103100_bib27","first-page":"S58","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo- and active-controlled clinical trial","volume":"22","author":"Silverman","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2024020319550103100_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"2024020319550103100_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2024020319550103100_bib30","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024020319550103100_bib31","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024020319550103100_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1359\/JBMR.0301228","article-title":"Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses","volume":"19","author":"Delmas","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020319550103100_bib33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020319550103100_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-005-0018-6","article-title":"Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep"},{"key":"2024020319550103100_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024020319550103100_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"2024020319550103100_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom"},{"key":"2024020319550103100_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020319550103100_bib39","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"key":"2024020319550103100_bib40","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2002.17.7.1139","article-title":"Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography","volume":"17","author":"Borah","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024020319550103100_bib41","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020319550103100_bib42","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.bone.2004.08.014","article-title":"Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy","volume":"35","author":"Delmas","year":"2004","journal-title":"Bone"},{"key":"2024020319550103100_bib43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","article-title":"Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial","volume":"287","author":"Barrett-Connor","year":"2002","journal-title":"JAMA"},{"key":"2024020319550103100_bib44","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1532-5415.2004.52420.x","article-title":"Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis","volume":"52","author":"Silverman","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"2024020319550103100_bib45","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.071206","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/23\/4\/525\/56571104\/5650230409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/23\/4\/525\/56571104\/5650230409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:50:11Z","timestamp":1710327011000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/23\/4\/525-535\/7599542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.071206","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,4,1]]},"published":{"date-parts":[[2008,4,1]]}}}